Media

A Review of Imaging Modalities in Prostate Cancer - Peter Pinto

Details
(Length of Interview: 17 min) Peter Pinto highlights the paradigm shift to the use of new imaging technology for a more accurate diagnosis of prostate cancer. Targeted MRI/Ultrasound (MR/US) guided biopsy vs TRUS biopsy, full body imaging options such as PET, and Axumin® (fluciclovine F 18) as a staging tool, with mention of metabolic and focal imaging are part of this comprehensive interview. As...

Nuclear Medicine and Lutetium 177 PSMA Therapies - Carmel Pezaro

Details
(Length of Discussion: 7 min) Charles Ryan and Carmel Pezaro have a conversation about Lutetium 177 PSMA based therapies in advanced prostate cancer. The experience she relates is unique to Australia leading to a difference in clinical options while presenting a potential conundrum with clinical trial designs. Biographies: Carmel Pezaro, MBChB, is a Senior Medical Oncologist and Senior Lecturer wo...

Imaging Modality and Recommendations Included in RADAR 3: Interview with Phillip Koo

Details
(Length of Discussion: 13 min) Phillip Koo, MD, FACS joins Alicia Morgans, MD, MPH to discuss the RADAR 3 recommendations in regards to imaging and detecting metastatic disease in prostate cancer. Biographies: Phillip J. Koo, MD, FACS Alicia Morgans, MD, MPH Related Content: A Clinician’s Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (Prostate Cancer Radiographic Asses...

The Incredible Shrinking nmCRPC - Phillip Koo

Details
(Length of Presentation: 12 min) Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient. His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He d...